natgillin/translations-raw huggingface dataset:
is hydrogen; alkyl; hydroxy; thio; alkyloxy optionally substituted with amino or mono or di(alkyl)amino or a radical of formula wherein Z is CH2, CH-R10, O, S, N-R10 and t is an integer equal to 1 or 2 and the dotted line represents an optional bond; alkyloxyalkyloxy; alkylthio; mono or di(alkyl)anuno wherein alkyl may optionally be substituted with one or two substituents each independently be selected from alkyloxy or Ar or Het or morpholinyl or 2-oxopyrrolidinyl; Ar; Het or a radical of formula wherein Z is CH2, CH-R10, O, S, N-R10; t is an integer equal to 1 or 2; and the dotted line represents an optional bond; 
R* je vodik; alkil; hiđroksi; tio; alkiloksi po izboru supstituiran sa amino ili mono ili di(alkilamino ili radikalom formule (kih N oz pri čemu Z je CH,, CH-R.", O, S, N-R'i t je cijeli broj jednak 1 ili 2, i isprekidana crta predstavlja vezu po izboru; alkiloksialkiloksi; alkiltio; mono ili di(alkiljamino pri čemu alkil može po izboru biti supstituiran sa jednim ili dva supstituenta od kojih je svaki nezavisno izabran između alkiloksi ili Ar ili Het ili morfolinil ili 2-oksopirolidinil; Ar, Het ili radikal formule
Panel according to one of the foregoing claims, wherein the first locking element is positioned at a distance from an upper side of the upward tongue. 
Panel (1, 42, 43, 46, 53, 57) prema jednom od prethodnih patentnih zahtjeva, pri čemu je prvi element (23, 64) za zaključavanje izveden na udaljenosti od gornje stranice prema gore isturenog jezička (19, 61).
The compound of claim 10, wherein the cancer is selected from the group consisting of breast cancer, head and neck cancer, lung cancer, ovarian cancer, pancreatic cancer, multiple myeloma, colorectal carcinoma, prostate cancer, melanoma, kaposi sarcoma, ewing's sarcoma, liver cancer, gastric cancer, medulloblastoma, brain tumors, and leukemia; 
Kombinacija iz patentnog zahtjeva 1, pri čemu je karcinom odabran iz grupe koja se sastoji od karcinoma dojke, karcinoma glave 1 vrata, karcinoma pluća, karcinoma jajnika, karcinoma gušterače, kolorektalnog karcinoma, karcinoma prostate, karcinoma stanica bubrega, melanoma, hepatocelularnog karcinoma, karcinoma cerviksa, sarkoma, tumora na mozgu, karcinoma želuca, multiplog mijeloma, leukemije i limfoma.
A compound of formula IIB: 
Spoj formule IIB:
An immunoconjugate having the formula Ab-(L-D)p, wherein: Ab is the anti-CD79b cysteine engineered antibody of any one of claims 1-5; 
Protutijelo anti-CD79b cisteinskog inženjeringa prema bilo kojem od zahtjeva 1 do 10, naznačeno time, da je protutijelo kovalentno priključeno na skupinu lijeka, pri čemu se stvara konjugat protutijelo-lijek.
An anti-IL6 antibody or antibody fragment thereof according to claim 1, comprising a VL chain and a VH chain, respectively, comprising the amino acid sequences of SEQ ID NO:2 and SEQ ID NO:3; SEQ ID NO:2 and SEQ ID NO:18; SEQ ID NO:2 and SEQ ID NO:19; SEQ ID NO:20 and SEQ ID NO:3; SEQ ID NO:20 and SEQ ID NO:18; or SEQ ID NO:20 and SEQ ID NO:19, or an antibody or antibody fragment thereof comprising a VL chain and a VH chain, respectively, comprising amino acid sequences having at least 90% or greater homology thereto. 
Anti-IL6 protutijelo ili njegov fragment u skladu s patentnim zahtjevom 1, sadrži VL lanac i VH lanac, redom, koji ima aminokiselinske sljedove SEQ ID NO:2 i SEQ ID NO:3; SEQ ID NO:2 i SEQ ID NO:18; SEQ ID NO:2 i SEQ ID NO:19; SEQ ID NO:20 i SEQ ID NO:3; SEQ ID NO:20 i SEQ ID NO:18; ili SEQ ID NO:20 i SEQ ID NO:19, ili protutijelo ili njegov fragment sadrži VL lanac i VH lanac, redom, koji ima aminokiselinske sljedove koji k tome imaju najmanje 90% ili više homologije.
As stated herein, antibodies and fragments thereof may be modified post-translationally to add effector moieties such as chemical linkers, detectable moieties such as for example fluorescent dyes, enzymes, substrates, bioluminescent materials, radioactive materials, and chemiluminescent moieties, or functional moieties such as for example streptavidin, avidin, biotin, a cytotoxin, a cytotoxic agent, and radioactive materials. 
(ii) dodatno sadrži efektorski ostatak koji je detektibilni ostatak ili funkcionalni ostatak, gdje navedeni detektibilni ostatak može biti fluorescentno bojilo, enzim, supstrat, bioluminescentni materijal, radioaktivni materijal, ili kemiluminescentni materijal, navedeni funkcionalni ostatak može biti streptavidin, avidin, biotin, citotoksin, citotoksično sredstvo, ili radioaktivni materijal.
The isolated nucleic acid molecule of claim 5, wherein the nucleic acid molecule is codon optimized for expression by Listeria monocytogenes. 
Izolirana molekula nuklemske kiseline prema zahtjevu 5, naznačena time, da je molekula nukleinske kiseline kođon optimiran za ekspresiju u Listeria monocytogenes.
A developer supply container according to any one of Claims 1 - 24, wherein said drive converting portion (2d, 3b) is provided with a cam mechanism configured and positioned to convert the rotational force generated by the rotation of said gear (2a) to the force for operating said pump portion (2b). 
Spremnik za nadopunjavanje razvijača u skladu s bilo kojim od patentnih zahtjeva 1-24, naznačen time što se navedeni dio za pretvorbu pogona (2d, 3b) ima zupčasti mehanizam tako konfiguriran i na takvom mjestu da pretvara silu vrtnje nastalu vrtnjom navedenog zupčanika (2a) u silu za rad navedenog crpnog dijela (2b).
The sulphate salt of claim 2, having formula Formula III 
Sulfatna sol iz patentnog zahtjeva 1, koja ima formulu III
for R1, a halogen atom, a cyano group, a C1-C6 alkyl group, a C1-C6 alkoxy group, or -J1-X1-R5 (wherein J1 represents a single bond or alkylene, X1 represents a single bond, an oxygen atom, or a sulfur atom, and R5 represents an optionally substituted cycloalkyl group, an optionally substituted cycloalkylalkyl group, an optionally substituted heterocycloalkyl group, an optionally substituted heterocycloalkylalkyl group, an optionally substituted aryl group, an optionally substituted aralkyl group, an optionally substituted heteroaryl group, or an optionally substituted heteroarylalkyl group); 
R' predstavlja atom vodika, cijano grupu, C1-C6 alkil grupu, C1-C6 alkil grupu alkoksi grupu ili -T'-X'-R> (gdje I! predstavlja jedinu vezu ili alkilen, X' predstavlja jedinu vezu, atom kisika ili atom sulfora i R> predstavlja po izboru supstituiranu cikloalkil grupu, po izboru supstituiranu cikloalkilalkil grupu, po izboru supstituiranu heterocikloalkil grupu, po izboru supstituiranu heterocikloalkilalkil grupu, po izboru supstituiranu aril grupu, po HR P20180373 T1 izboru supstituiranu aralkil grupu, po izboru supstituiranu heteroaril grupu, po izboru supstituiranu heteroarilalkil grupu),
The method according to claim 23, where a waterproof reinforcement element, or a waterproof heat-sealing tape, which is elastic and made of synthetic material, is applied directly to the inner surface of the lower edge of the membrane. The method according to claim 1, wherein said sole is overmolded directly onto the upper part. 
Postupak u skladu s jednim ili više od prethodnih patentnih zahtjeva, naznačen time, da se nepromočivi element za ojačavanje, poput nepromočive termoljepljive vrpce, koja je poželjno elastična 1 izrađena od sintetičkih materijala, postavlja izravno na unutarnju površinu donjeg ruba membrane (13).
Functionally, the sugar replacement composition according to the invention can replace sugar in ice cream, particularly in scoop ice cream. 
Stoga sastavina koja zamjenjuje šećer, prema ovom izumu, može zamijeniti šećer u sladoledu, napose u slastičarskom sladoledu (kuglice).
The pharmaceutical composition of claim 2, wherein the composition is formulated in phosphate-buffered saline (PBS) and 10% glycerol. 
Farmaceutski sastav 17 zahtjeva 3, naznačeno time da je sastav formuliran u sterilnom obliku, podobnom za ubrizgavanje.
The antibody or fragment of claim 1, which is recombinantly produced. 
Protutijelo ili fragment iz patentnog zahtjeva 1, koje je rekombinantno proizvedeno.
The method of claim 44, wherein the pain is inflammatory pain, neuropathic pain, pain is associated with cancer, or pain is associated with bone fracture. 
Tvar ili farmaceutski sastav za uporabu definiranu u patentnom zahtjevu 27, pri čemu je bol upalna bol, neuropatska bol, bol povezana s rakom, bol povezana s operativnim zahvatom ili bol povezana s frakturom kostiju.
The method according to any one of claims 1-5, wherein the addition of the WT1 peptide to the antigen-presenting cell is practiced by the addition of the WT1 peptide, the addition of an expression vector comprising the polynucleotide encoding the WT1 peptide or the addition of a cell including the expression vector. 
Postupak prema bilo kojem od zahtjeva 1-4, naznačen time da se dodavanje WT1 peptida u antigen prezentirajuću stanicu prakticira s dodavanjem WT1 peptida, dodavanjem ekspresijskog vektora koji sadrži polinukleotid koji kodira WT1 peptid ili dodavanjem stanice koja sadrži ekspresijski vektor.
An isolated IL-23p19 antibody, comprising: 
izoliranim IL-23p19 antitijelom koje sadrži
Moreover, once again during this phase, the plate may tilt due to unbalanced traction, causing aim errors and contributing to the loss of the line of fire following the recoil. 
Osim toga za vrijeme ponavljanja te faze ploča se može nakriviti zbog neuravnoteženog povlačenja, što ima za posljedicu greške kod ciljanja i doprinosi gubitku pravca pucanja nakon trzanja.
said lactam is formed by an amide bond between a non-a, non-side-chain amino group of X1 and the side chain carboxyl group of X7, wherein X1 and X7 are, respectively, a pair selected from the group consisting of B-Ala/Asp, B-Ala/Glu, 5-amino-valeryl/Asp, 5-aminovaleryl/Glu, 4-AMB/Glu, 4-AMPA/Asp, and 4-AMPA/Glu, and R1 is absent; or 
navedeni laktam tvori se amidnom vezom između amino skupine u X1, koja nije ni a- niti amino skupina u pobočnom lancu, i karboksilne skupine u pobočnom lancu u X7, gdje X1 i X7 čine par, koji se bira iz skupine koju čine B-Ala/Asp, B-Ala/Glu, 5-aminovaleril/Asp, 5-aminovaleril/Glu, 4-AMB/Glu, 4-AMPA/Asp, te 4-AMPA/Glu, a R1 je odsutan; ili
each of R' and R" is selected from hydrogen or C1-6 alkyl, or -NR'R" together are joined to form a substituted or unsubstituted, saturated or unsaturated 3-10 membered ring, which may optionally include heteroatoms which may be the same or different and are selected from O, NRf (wherein Rf is hydrogen or substituted or unsubstituted alkyl) or S; and X is CR3 wherein R3 is independently hydrogen, halogen, hydroxyl or NH2. 
svako R’ i R" je odabrano od vodika ili C1-6 alkila, ili -NR’R" zajedno su spojeni da oforme supstituiran ili nesupstituiran, zasićen ili nezasićen 3-10 člani prsten, koji može izborno obuhvatiti heteroatome koji mogu biti jednaki ili drugačiji i odabrani su od O, NRf (pri čemu Rf je vodik ili supstituiran ili nesupstituiran alkil) ili S; i X je CR3 pri čemu R3 je neovisno vodik, halogen, hidroksil ili NH2.
The plant of claim 12, wherein the domotic controllers (15) are supplied by the rechargeable battery (13). 
Postrojenje patentnog zahtjeva 12, pri čemu se domotični upravljači (15) opskrbljivani pomoću punjive baterije
in part (f), the heavy chain comprises a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:123 and/or the light chain comprises a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:122; 
(h) -VH sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 123i VL sekvencu koja ima najmanje 95% identiteta sekvence od aminokiselinske sekvence SEQ ID NO: 122;
A pharmaceutical composition comprising an amount of glatiramer acetate and an amount of rasagiline or a pharmaceutically acceptable salt thereof for alleviating a symptom of a form of multiple sclerosis in a subject by periodically administering the pharmaceutical composition to the subject. 
Farmaceutski sastav koji sadrži neku količinu glatiramer acetata i neku količinu rasagilina ili njegove farmaceutski prihvatljive soli, naznačen time, da služi ublažavanju simptoma oblika multiple skleroze kod pacijenta, periodičkim davanjem farmaceutskog sastava pacijentu.
The antibody for use of claim 17, wherein the heavy chain comprises the amino acid sequence of SEQ ID NO: 52 and the light chain comprises the amino acid sequence of SEQ ID NO: 53. 
SEKVENCE: 53. Izolirano protutijelo u skladu s patentnim zahtjevom 8, naznačeno time, da teški lanac sadrži aminokiselinski slijed IDENTIFIKACIJSKOG BR. SEKVENCE: 52 i laki lanac sadrži aminokiselinski slijed IDENTIFIKACIJSKOG BR.
The system of any of claims 16 to 19, wherein the sealing material is selected from the group comprising fibres, paper, cotton, viscous paste, foam. 
Sustav u skladu s bilo kojim od patentnih zahtjeva 15 do 17, u kojemu je materijal za brtvljenje (8) odabran iz skupine koja sadržava vlakna, papir, pamuk, viskoznu pastu, pjenu.
The compound for use according to claim 4 wherein said compound of Formula II is for administration in the form of a transdermal patch, ointment, lotion, cream, or gel. 
Spoj za uporabu prema zahtjevu 6, naznačen time da je navedeni spoj za davanje u obliku transdermalnog flastera, masti, losiona, kreme ili gela.
In order to avoid premature curing of the polymerizable resin base, it may be advantageous to prepare and store the composite material as a two-component material intended for mixing immediately prior to use. 
Da bi se izbjeglo prerano očvršćivanje baze za smolu koja polimerizira, može biti pogodno pripraviti i čuvati kompozitni materijal kao dvokomponentni materijal kojeg treba miješati neposredno prije upotrebe.
An audio signal encoding method for encoding an audio signal including a plurality of frames, using a first encoding means operating under a linear predictive coding scheme and a second encoding means operating under a coding scheme which is different from the linear predictive coding scheme, the audio signal encoding method comprising: 
Postupak kodiranja audio signala, namijenjen kodiranju audio signala koji sadrži više okvira, uz pomoć prvog kodera (13), koji radi prema linearnoj prediktivnoj shemi kodiranja, i drugog kodera (14), koji radi prema shemi kodiranja koja se razlikuje od linearne prediktivne sheme kodiranja, naznačen time što se postupak kodiranja audio signala sastoji u:
A compound of Formula I: or an enantiomer or a mixture of enantiomers thereof, or a pharmaceutically acceptable salt, solvate, hydrate, co-crystal, clathrate, or polymorph thereof, wherein: 
No Å O H ili njegov enantiomer ili smjesa enantiomera ili njegova farmaceutski prihvatljiva sol, solvat, hidrat, kokristal, klatrat ili polimorf, naznačen time, da:
SDS was measured by the acridine orange assay [35]. 
SDS je mjeren pomoću akridin oranža [35].
Ercan-Fang et al., (1997) (J. Pharmacol. 
Ercan-Fang i suradnici, (1997) (J. Pharmacol.
A stable aqueous paracetamol solution for use in IV infusion comprising a 2-hydroxypropyl-beta-cyclodextrin as a stabilizing-dissolving compound wherein the molar ratio of paracetamol to 2-hydroxypropyl-beta-cyclodextrin is 100:1 to 0.1:1, and the aqueous solution comprises 2 mg to 200 mg of paracetamol per ml solution, further comprising EDTA and monothioglycerol as stabilizing compounds, wherein the concentration of EDTA is 0.0015 mg to 1 mg per ml solution and the concentration of monothioglycerol is 0.015 mg to 1 mg per ml solution. 
Stabilna vodena otopina paracetamola za uporabu u IV infuziji sadrži 2-hidroksipropil-beta-ciklodekstrin kao tvar za stabilizaciju i otapanje pri čemu je molarni omjer paracetamola prema 2-hidroksipropil-beta-ciklodekstrinu 100:1 do 1:1, a vodena otopina sadrži 2 mg do 200 mg paracetamola po mL otopine, nadalje sadrži EDTA i monotioglicerol kao stabilizirajuće tvari, pri čemu je koncentracija EDTA 0.0015 mg do 1 mg po mL otopine i koncentracija monotioglicerola je 0.015 mg do 1 mg po mL otopine.
A vector comprising a nucleic acid sequence or sequences according to claim 3, preferably wherein the vector is a plasmid or recombinant viral vector. 
Vektor koji sadrži slijed nukleinske kiseline u skladu s patentnim zahtjevom 4.
Panel according to one of the foregoing claims, wherein the second locking element comprises at least one outward bulge, and that the first locking element comprises at least one recess, which outward bulge is adapted to be at least partially received in a recess of an adjacent coupled panel for the purpose of realizing a locked coupling. 
Panel (1, 42, 43, 46, 53, 57) prema jednom od prethodnih patentnih zahtjeva, pri čemu drugi element (30, 69) za zaključavanje obuhvaća najmanje jednu vanjsku izbočinu i što prvi element (23, 64) za zaključavanje obuhvaća najmanje jedno udubljenje, gdje je vanjska izbočina prilagođena da bude najmanje djelomično smještena u udubljenje susjednog povezanog panela (1, 42, 43, 46, 53, 57) radi ostvarivanja zaključanog spoja.
The compounds were added in vitro to determine their inhibitory activity on LDL oxidation induced by haemin and H202. 
Spojevi su dodani in vitro za određivanje njihovog inhibitorskog djelovanja na LDL oksidaciju izazvanu s heminom i H2O2.
The nonwoven fabric of any one of the foregoing claims, wherein the calcium carbonate is present in the nonwoven fabric in an amount from 0.1 to 50 wt.-%, preferably from 0. 
Netkani materijal prema bilo kojem od prethodnih zahtjeva, naznačen time da je kalcijev karbonat prisutan u netkanom materijalu u količini od 0.
A container for a liquid pharmaceutical composition, the container containing a liquid pharmaceutical composition ready for injection and containing interferon-B as active ingredient, characterised by comprising a closure means coated by an inert fluorinated material and wherein the internal surface of the container is coated by an inert material. 
Spremnik za tekući farmaceutski pripravak, te navedeni spremnik sadrži tekući farmaceutski pripravak spreman za ubrizgavanje, te kao aktivni sastojak sadrži interferon-B, naznačen time da sadrži sredstva za zatvaranje obložena inertnim fluoriranim materijalom, te time da je unutarnja površina spremnika obložena sa inertnim materijalom.
An antibody-drug conjugate compound or antigen-binding fragment-drug conjugate compound of the following formula: 
HR P20161345 T1 PATENTNI ZAHTJEVI e Spoj konjugata ligand-lijek prema slijedećoj formuli:
a second domain VHB being a heavy chain variable domain specific for CD19; 
- < drugu domenu VB koja predstavlja varijabilnu domenu teškog lanca specifičnu za drugi antigen B;
The tissue-targeting complex for use as claimed in claim 7 wherein said disease is a carcinoma, sarcoma, myeloma, lukemia, lymphoma or mixed type cancer. 
Kompleks za ciljanje tkiva za uporabu prema zahtjevu 6 naznačen time da je navedena bolest karcinom, sarkom, mijelom, leukemija, limfom ili karcinom mješovitog tipa.
Method according to claim 1,2,3 or 4, wherein the speed of the water inside the cavity is about as high as a forward speed of the vessel. 
Postupak prema zahtjevu 1, 2, 3 ili 4, gdje je brzina vode unutar šupljine otprilike tolika koliko i brzina plovila.
FIGS. 3 and 4 show a further variant of the invention, and more particularly only the bottom end of this valiant. 
Slike 3 1 4 prikazuju jednu daljnju varijantu ovog izuma, i posebno samo donji kraj te varijante izuma.
In a still further aspect, the present invention provides the use of a compound of formula (1), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof, as hereinbefore defined for use as a medicament for the treatment of asthma, allergic rhinitis, cancer, COPD, rheumatoid arthritis, psoriasis, inflammatory bowel diseases, osteoarthritis or osteoporosis. 
HR P20140023 T1 Farmaceutski pripravak prema zahtjevu 21 naznačen time da je za liječenje astme, alergijskog rinitisa, KOPB, upalne bolesti crijeva, sindroma iritabilnog crijeva, osteoartritisa, osteoporoze, reumatoidnog artritisa, ili psorijaze.
to a body cavity or to the skin. 
u tjelesnu šupljinu.
A method for producing an aripiprazole suspension comprising the steps of: 
PATENTNI ZAHTJEVI Postupak za proizvodnju suspenzije aripiprazola koji sadrži korake:
A compound of either of the following formulae: wherein R1 is selected from the group consisting of OR2 and NR3R4, and R2, R3 and R4 are each independently selected from the group consisting of H, alkyl, alkenyl, alkynyl, alkoxy, cycloalkyl, aryl, alkylaryl, arylalkyl, and heteroaryl groups, wherein: 
"R! gdje R, se bira iz skupine koju čine OR, i NR:Ru, gdje svakog od Rx, R3 i Ra se neovisno bira iz skupine koju čine H, alkilne, alkenilne, alkinilne, alkoksi, cikloalkilne, arilne, alkilarilne, arilalkilne i heteroarilne skupine, gdje:
The compounds represented by the aforementioned formula (I) may form a salt, Examples of the salt include, when an acidic group exists, salts of alkali metals and alkaline earth metals such as lithium, sodium, potassium, magnesium, and calcium; salts of ammonia and amines such as methylamine, dimethylamine, trimethylamine, dicyclohexylamine, tris(hydroxymethyl)aminomethane, N,N-bis (hydroxyethyl)piperazine, 2-amino-2-methyl-1-propanol, ethanolamine, N-methylglucamine, and L-glucamine; or salts with basic amino acids such as lysine, δ-hydroxylysine, and arginine. 
Spojevi prikazani gore navedenom formulom (I) mogu tvoriti sol. Primjeri soli uključuju, kada je prisutna kisela skupina, soli alkalnih i zemnoalkalnih metala, poput litija, natrija, kalija, magnezija 1 kalcija; soli amonijaka i amina, poput -metilamina, < dimetilamina, trimetilamina, dicikloheksilamina, tris(hidroksimetiljaminometana, N,N-bis (hidroksietil)piperazina, 2-amino-2-metil-1-propanola, etanolamina, N-metilglukamina i L-glukamina; ili soli s bazičnim aminokiselinama, poput lizina, 8-hidroksilizina i arginina.
More particularly, an object of the invention resides in a pharmaceutical composition comprising, in the form of a solution: 
PATENTNI ZAHTJEVI Nana Farmaceutski sastav koji sadrži, u obliku otopine:
A pharmaceutical formulation comprising AMG 416 hydrochloride in aqueous solution, wherein the formulation has a pH of 2.0 to 5.0. 
PATENTNI ZAHTJEVI 1. - Farmaceutska formulacija koja sadrži AMG 416 u vodenoj otopini, pri čemu formulacija ima pH od 2.0 do 5.0.
A solvent for the buprenorphine base or pharmaceutically acceptable salt thereof may be included as about 0.1 to about 30% (by weight). 
Otapalo buprenorfinske baze ili njegove farmaceutski prihvatljive soli može biti uključeno s približno 0.1 do približno 30% (mase). HR P20070476 T3
is an amino acid residue selected from the group consisting of alanine (A) and tyrosine (Y), 
XÂ« je aminokiselinski ostatak odabran iz skupine koju čine alanin (A) 1 tirozin (Y),
amplifying the nucleic acid sequence corresponding to a specific region of the EGFR gene by means of PCR using a Protein-Nucleic Acid probe wherein said Protein-Nucleic Acid probe is capable of specifically recognising and hybridising with the EGFR wild type sequence thereby inhibiting its amplification; and 
amplifikaciji slijeda nukleinske kiseline koji odgovara specifičnoj regiji EGFR gena PCR-om pomoću proteinsko-nukleinskokiselinske sonde, gdje navedena proteinsko-nukleinskokiselinska sonda može specifično prepoznati i hibridizirati sa slijedom EGFR-a divljeg tipa, inhibirajući tako njegovu amplifikaciju; i
is halo, alkyl, OH, alkoxy, thioalkyl, trifluoromethoxy; or two R1 on adjacent atoms, taken together, form wherein J is selected from the group consisting of CH2, CF2, or C(CH3)2; 
je halogen, alkil, OH, alkoksi, tioalkil, trifluorometoksi; ili dva R1 na susjednim atomima, zajedno, tvore [image] pri čemu J je odabran iz skupine koju čine CH2, CF2, ili C(CH3)2;
The method according to claim 5, wherein the rasagiline and the acid are mixed in the presence of a solvent. 
Postupak prema patentnom zahtjevu 7, naznačen time, da se rasagilin i kiselina miješanju uz primjenu miješalice.